Focus: Structure Therapeutics is a public biotech company developing oral small molecule drugs designed to deliver biologic-like activity and specificity, currently focused on metabolic and infectious diseases.
Profile data last refreshed 7h ago · AI intelligence enriched 1w ago
Hot — 349 jobs added in 30d
Net +322 (349 new, 27 removed). Aggressive expansion phase.
Best suited for scientists and clinical professionals seeking early-stage equity exposure in obesity/metabolic disease; stability-focused candidates should evaluate cash runway carefully.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Structure Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Structure Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles